Resverlogix says new journal studies link apabetalone to lower heart-failure risk

• Resverlogix reported publication of two peer-reviewed studies on apabetalone mechanisms tied to preventing heart failure.
• Findings were presented now through journal publication, building on earlier clinical signals from BETonMACE.
• One study linked apabetalone to improved metabolic function, supporting potential benefit for fatty liver disease.
• The other study suggested reduced formation of harmful cardiac scar tissue, consistent with fewer heart-failure hospitalizations seen previously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Resverlogix Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202609100715NEWSFILECNPR____20260910_313789_1) on September 10, 2026, and is solely responsible for the information contained therein.